Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways Data to be presented at Corbus Pharmaceuticals' upcoming R&D day on March 13th

• Published in: Marketwired
• Format: Trade Publication Article
• Language: English
• Published: Toronto Intrado Digital Media Canada Inc 08.03.2017
• Subjects: Appointments & personnel changes; Health risk assessment; Pharmaceutical industry; Product development; New York

CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael L. Whitfield, Ph.D., Professor of Molecular and Systems Biology, Dartmouth Geisel School of Medicine and Scientific Founder of Celdara Medical, LLC, will present data demonstrating JBT-101 treatment of systemic sclerosis patients inhibits gene expression of key regulatory proteins in molecular pathways associated with activating inflammation and fibrosis, while increasing gene expression in pathways associated with lipid metabolism responsible for resolving inflammation. Dr. Whitfield will present data showing distinct differences in gene expression profiles between skin biopsy samples from systemic sclerosis patients receiving JBT-101 and those receiving placebo. [...]expression of gene transcripts associated with bioactive lipid metabolism pathways, including lipid biosynthetic enzymes and fatty acid metabolism enzymes were increased in skin biopsies from subjects receiving JBT-101, but not placebo. The disease process in systemic sclerosis includes activation of the immune system, with damage to small blood vessels and fibrosis of the skin on internal organs, including lungs, heart, kidneys, gastrointestinal tract and musculoskeletal system. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E...